Abstract 3745
Background
Small cell lung cancer (SCLC), a highly invasive neuroendocrine tumor, accounts for approximately 15% of all new diagnosed lung cancer. Primary disease is highly sensitive to chemotherapy as well as radiotherapy, recurrences occur quickly, and less effective to subsequent therapies than the initial chemotherapy, the response rate of second-line therapy topotecan is only 22%. Drug resistance, is the main reason for failure of SCLC chemotherapy. Here, we quantitatively analyzed the proteomes of Cisplatin/Etoposide-resistant and -sensitive ES-SCLC patients from minute amounts of formalin-fixed and paraffin-embedded (FFPE) tissues. FABP5 was identified to be related with primary chemosensitivity, and may be an important mediator of Cisplatin/Etoposide-induced cell death.
Methods
51 tissue samples were collected from ES-SCLC patients who underwent Cisplatin and Etoposide chemotherapy in Zhe Jiang Cancer Hospital from January 2015 to November 2017. The 51 cases included 23 chemosensitive patients and 28 chemoresistant patients. System-wide quantitative proteomics approach was applied on the cohort of chemo-resistant and -sensitive tissues, and label free protein quantification was performed. Realtime-PCR was performed to assess the mRNA expression in H69 and multi-drug resistant H69AR cells.
Results
A total of 4,485 proteins were identified and quantified, more than 50% proteins were 10-70KD, Proteins with a fold difference greater than 1.5 (up/down) and a P value (t test) less than 0.05 were considered differentially expressed proteins, few overall proteome changes across the two groups. Comparison of the two-group found that FABP5 was significantly decreased in drug-resistant patients. Consistent with the protein level in tumor tissues, FABP5 mRNA was down-regulated in H69AR cells. FABP5 expression strongly correlated with decreased disease-free survival and overall survival in ES-SCLC patients.
Conclusions
These data revealed FABP5 may serve as a potential biomarker for primary chemoresistance and prognostic factor for patients with ES-SCLC, which need further research.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yamei Chen.
Funding
National Natural Science Foundation of China (grant numbers 81672972).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5444 - Analysis of the tumor microenvironment and tumor genotype through different stages of lung adenocarcinoma
Presenter: Peter Zink
Session: Poster Display session 1
Resources:
Abstract
3124 - Does Progress achieved in the Treatment of Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC) reach the Elderly Population?
Presenter: Jorune Suipyte
Session: Poster Display session 1
Resources:
Abstract
5142 - Prognostic factors for non-small cell lung cancer patients with driver mutation negative and brain metastases (HOT 1701)
Presenter: Yoshihito Ohhara
Session: Poster Display session 1
Resources:
Abstract
1580 - A novel risk classification system based on nomogram scores to predict survival of patients presenting with brain metastases at the first diagnosis of NSCLC
Presenter: Pengfei Cui
Session: Poster Display session 1
Resources:
Abstract
4442 - Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: Xinran Ma
Session: Poster Display session 1
Resources:
Abstract
5405 - Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model
Presenter: Parneet Kaur Cheema
Session: Poster Display session 1
Resources:
Abstract
1893 - SMARCA4 Deficient Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Genomic Profiling (CGP) Study
Presenter: Stephen Graziano
Session: Poster Display session 1
Resources:
Abstract
5582 - Exploring Resistance to Nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study]
Presenter: Sara Pilotto
Session: Poster Display session 1
Resources:
Abstract
1408 - DNA damage repair deficiency is associated with early resistance to crizotinib: whole-genome analysis in non-small cell lung cancer patients with ALK-fusion
Presenter: Dongyun He
Session: Poster Display session 1
Resources:
Abstract
5751 - Phase 3 ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
Presenter: Sanjay Popat
Session: Poster Display session 1
Resources:
Abstract